Table 2.
Univariable Cox regression analyses of factors associated with overall survival and progression-free survival
| Overall survival | Progression-free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| β | SE | HR (95% CI) | P value | β | SE | HR (95% CI) | P value | |
| Age, ≤ 65 vs. >65 | -0.049 | 0.447 | 0.95 (0.40–2.29) | 0.913 | -0.208 | 0.338 | 0.81 (0.42–1.58) | 0.538 |
| Sex, male vs. female | 0.697 | 0.603 | 2.01 (0.62–6.55) | 0.248 | 0.345 | 0.435 | 1.41 (0.60–3.31) | 0.427 |
| Hepatitis virus infection, yes vs. no | 0.011 | 0.405 | 1.01 (0.46–2.24) | 0.979 | 0.221 | 0.342 | 1.25 (0.64–2.44) | 0.518 |
| Cardiovascular diseases, yes vs. no | 0.260 | 0.298 | 1.30 (0.72–2.32) | 0.383 | 0.079 | 0.353 | 1.09 (0.55–2.18) | 0.823 |
| T2DM, yes vs. no | 0.663 | 0.446 | 1.94 (0.81–4.65) | 0.138 | 0.012 | 0.302 | 1.02 (0.56–1.83) | 0.967 |
| Antiviral treatment, yes vs. no | -0.531 | 0.345 | 0.59 (0.30–1.16) | 0.124 | -0.225 | 0.265 | 0.80 (0.48–1.34) | 0.394 |
| Child-Pugh stage, A vs. B | -0.219 | 0.483 | 0.80 (0.31–2.07) | 0.651 | -0.213 | 0.334 | 0.81 (0.42–1.56) | 0.524 |
| ECOG PS, 2 vs. 0–1 | 0.244 | 0.731 | 1.28 (0.31–5.35) | 0.738 | 0.242 | 0.596 | 1.27 (0.40–4.10) | 0.685 |
| PLT, ≤ 100 vs. >100, ×109/L | 0.090 | 0.489 | 1.09 (0.42–2.86) | 0.854 | -0.091 | 0.410 | 0.91 (0.41–2.04) | 0.825 |
| PT, > 14 vs. ≤14, s | 0.680 | 0.730 | 1.98 (0.47–8.25) | 0.351 | 0.193 | 0.471 | 1.21 (0.48–3.06) | 0.682 |
| Scr, ≤ 84 vs. >84, umol/L | -0.299 | 0.423 | 0.74 (0.32–1.70) | 0.480 | -0.151 | 0.371 | 0.86 (0.42–1.78) | 0.685 |
| Blood glucose, ≤ 6.1 vs. >6.1, mmol/L | -0.107 | 0.371 | 0.90 (0.43–1.86) | 0.774 | -0.252 | 0.302 | 0.78 (0.43–1.40) | 0.403 |
| TBIL, > 17.1 vs. ≤17.1, umol/L | 0.562 | 0.340 | 1.76 (0.90–3.42) | 0.098 | 0.212 | 0.266 | 1.24 (0.73–2.08) | 0.426 |
| ALB, > 35 vs. ≤35, g/L | -0.582 | 0.373 | 0.56 (0.27–1.16) | 0.118 | -0.157 | 0.322 | 0.85 (0.45–1.61) | 0.626 |
| AFP, ≤ 400 vs. >400, ng/mL | -1.168 | 0.390 | 0.31 (0.15–0.67) | 0.003 | -1.204 | 0.327 | 0.30 (0.16–0.57) | < 0.001 |
| NLR, ≤ 2.77 vs. >2.77 | -2.154 | 0.603 | 0.12 (0.04–0.38) | < 0.001 | -1.325 | 0.349 | 0.27 (0.13–0.53) | < 0.001 |
| DCP, ≤ 400 vs. >400, mAU/ml | -0.573 | 0.334 | 0.56 (0.29–1.09) | 0.087 | -0.399 | 0.275 | 0.67 (0.39–1.15) | 0.147 |
| HBV-DNA, ≤ 1000 vs. >1000, copies/ml | -1.064 | 0.372 | 0.35 (0.17–0.72) | 0.004 | -1.042 | 0.314 | 0.35 (0.19–0.65) | 0.001 |
| Tumor diameter, ≤ 10 vs. >10, cm | -0.490 | 0.367 | 0.61 (0.30–1.26) | 0.181 | -0.202 | 0.293 | 0.82 (0.46–1.45) | 0.489 |
| Tumor number, single vs. multiple | -0.528 | 0.605 | 0.59 (0.18–1.93) | 0.383 | -0.338 | 0.524 | 0.71 (0.26–1.99) | 0.519 |
| Extrahepatic metastasis, yes vs. no | 1.122 | 0.611 | 3.07 (0.93–10.17) | 0.066 | 0.817 | 0.598 | 2.26 (0.70–7.31) | 0.172 |
| Macrovascular invasion, yes vs. no | 0.669 | 0.340 | 1.95 (1.00–3.80) | 0.050 | 0.462 | 0.278 | 1.59 (0.92–2.74) | 0.097 |
Notes: T2DM, type 2 diabetes mellitus; ECOG PS, Eastern Cooperative Oncology Group performance status; PLT, platelets; PT, prothrombin time; Scr, serum creatinine; TBIL, total bilirubin; ALB, albumin; AFP, alpha-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; DCP, des-γ-carboxy-prothrombin